Technical Analysis for IOVA - Iovance Biotherapeutics, Inc.

Grade Last Price % Change Price Change
C 12.36 -6.29% -0.83
IOVA closed down 6.29 percent on Friday, April 12, 2024, on 45 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
5 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down

Date Alert Name Type % Chg
180 Bearish Setup Bearish Swing Setup 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Lower Bollinger Band Walk Weakness 0.00%
BB Squeeze + Lower Band Touch Range Contraction 0.00%
Below Lower BB Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Stochastic Buy Signal Bullish -6.29%
Bollinger Band Squeeze Range Contraction -6.29%
Lower Bollinger Band Walk Weakness -6.29%

   Recent Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Iovance Biotherapeutics, Inc. Description

Iovance Biotherapeutics, Inc., formerly Lion Biotechnologies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. The Company's lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients' tumors, for the treatment of metastatic melanoma. As of December 31, 2016, it had an on-going Phase II clinical trial of its lead product candidate, LN-144, TIL for the treatment of metastatic melanoma. The Company is developing LN-145 to treat cervical and head and neck cancers. It is collaborating with the National Cancer Institute to evaluate unmodified TIL in other solid tumor indications, such as ocular melanoma, bladder, breast and lung cancer. It is collaborating with the NCI to evaluate TIL in combination with the checkpoint inhibitor, Keytruda.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Solid Tumors Immune System Immunotherapy Cancer Treatment Oncology Cancer Immunotherapy Cell Therapy Melanoma Antineoplastic Drugs Cancer Cell Lymphocytes Checkpoint Inhibitor Adoptive Cell Transfer Head And Neck Cancer Immunotherapy Products National Cancer Institute Cancer Immunotherapy Product Metastatic Melanoma Pembrolizumab Tumor Infiltrating Lymphocytes Breast And Lung Cancer Ocular Melanoma

Is IOVA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 18.33
52 Week Low 3.21
Average Volume 10,049,415
200-Day Moving Average 8.03
50-Day Moving Average 13.38
20-Day Moving Average 13.91
10-Day Moving Average 13.35
Average True Range 0.92
RSI (14) 39.39
ADX 15.52
+DI 18.76
-DI 25.55
Chandelier Exit (Long, 3 ATRs) 13.13
Chandelier Exit (Short, 3 ATRs) 14.88
Upper Bollinger Bands 15.45
Lower Bollinger Band 12.37
Percent B (%b) 0.0
BandWidth 22.16
MACD Line -0.30
MACD Signal Line -0.03
MACD Histogram -0.2741
Fundamentals Value
Market Cap 3.16 Billion
Num Shares 256 Million
EPS -2.08
Price-to-Earnings (P/E) Ratio -5.94
Price-to-Sales 3590.82
Price-to-Book 3.49
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 13.83
Resistance 3 (R3) 13.92 13.53 13.59
Resistance 2 (R2) 13.53 13.15 13.48 13.50
Resistance 1 (R1) 12.94 12.92 12.75 12.85 13.42
Pivot Point 12.55 12.55 12.45 12.50 12.55
Support 1 (S1) 11.96 12.17 11.77 11.87 11.30
Support 2 (S2) 11.57 11.94 11.52 11.22
Support 3 (S3) 10.98 11.57 11.14
Support 4 (S4) 10.89